Announcements Trials
Browse Landscape

Phase

Phase NA 2Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 50Pancreatic Neoplasms 33Prostatic Neoplasms 31Brain Neoplasms 28Lung Neoplasms 26Neoplasm Metastasis 24Melanoma 21Carcinoma, Hepatocellular 20Breast Neoplasms 17Carcinoma, Renal Cell 12Colorectal Neoplasms 11Squamous Cell Carcinoma of Head and Neck 10Neoplasms 9Small Cell Lung Carcinoma 7Urinary Bladder Neoplasms 5Recurrence 5Head and Neck Neoplasms 5Glioblastoma 5Adenocarcinoma of Lung 5Sarcoma 4Liver Neoplasms 4Kidney Neoplasms 4Uterine Cervical Neoplasms 3NSCLC 3Clear-cell metastatic renal cell carcinoma 3Cholangiocarcinoma 3Uveal Melanoma 2Unresectable Locally Recurrent Rectal Cancer 2Triple Negative Breast Neoplasms 2Rectal Neoplasms 2

Interventions

Fluorouracil 4Oxaliplatin 3Capecitabine 3toripalimab 2dehydroftorafur 2Specimen Handling 2Magnetic Resonance Spectroscopy 2Leucovorin 2Biopsy 2tremelimumab 1trametinib 1tislelizumab 1temoporfin 1sacituzumab govitecan 1lenvatinib 1gemcitabine-oxaliplatin regimen 1durvalumab 1binimetinib 1Stents 1Sorafenib 1Radiosurgery 1Hydroxychloroquine 1Gemcitabine 1Erlotinib Hydrochloride 1Cisplatin 13-(4-chlorophenyl)-adamantane-1-carboxylic acid (pyridin-4-ylmethyl)amide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Klatskin Tumor × Radiosurgery × Clear all
NCT07030140 2026-05-01

Phase II Study of Neoadjuvant Tislelizumab Plus Radiotherapy and GP Chemotherapy for Borderline/Unresectable Hilar Cholangiocarcinoma

Shandong Cancer Hospital and Institute

Phase 2 Recruiting
38 enrolled
Gastrointestinal

Bile Duct Neoplasms, Biliary Tract Neoplasms, Cholangiocarcinoma, Klatskin Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡